Alembic Limited has fixed Tuesday, August 4, 2026, as the record date to determine shareholder eligibility for the dividend payment for FY26, subject to approval at the Annual General Meeting. The 119th Annual General Meeting of the company is scheduled for Tuesday, August 11, 2026, at 5:00 p.m. IST through Video Conferencing or Other Audio Visual Means. The meeting will be conducted in accordance with the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Annual Report, including the Notice of AGM and the process for e-voting, will be sent only to members whose email addresses are registered with the company or depositories. The documents will also be available on the company's website and the websites of BSE Limited and National Stock Exchange of India Limited.

Shareholders holding securities in physical form must ensure their folios are updated with Permanent Account Number, contact details, mobile number, bank account details, and specimen signature to receive dividends electronically. As per Regulation 12 of the SEBI Listing Regulations, 2015, all dividend payments must be made electronically, and no physical warrants or cheques will be issued.

Members holding shares in physical form are requested to submit the appropriate forms to the company's Registrar and Transfer Agent, MUFG Intime India Pvt. Ltd., by Friday, July 31, 2026. Those holding shares in demat mode should update their details with their Depository Participants.

The company stated that tax deducted at source (TDS) on dividends will apply as per the provisions of the Income Tax Act, 2025. The TDS rate will vary based on the shareholder's residential status and submitted documents. Members are advised to update their PAN and submit relevant documents such as Tax Residency Certificate or Lower Tax Certificate to the Registrar to avoid higher tax deduction.

Key AGM Details

Alembic Limited reported its audited financial results for the quarter and financial year ended March 31, 2026. The company's consolidated net profit after tax and share of associate's profit stood at Rs 6,713 lakh for the fourth quarter, a decrease from Rs 6,845 lakh in the corresponding period of the previous year. Revenue from operations for the quarter remained relatively steady at Rs 6,004 lakh compared to Rs 6,027 lakh in the same quarter last year.

Key Financial Performance

The board approved the audited financial results and recommended a dividend of Rs 2.40 per equity share, representing 120% of the face value of Rs 2/- each, for the fiscal year ended March 31, 2026. This dividend is subject to shareholder approval at the ensuing Annual General Meeting.

For the full financial year, the company reported a consolidated net profit after tax and share of associate's profit of Rs 31,738 lakh, compared to Rs 31,068 lakh in the previous year. Total revenue from operations for the year increased to Rs 23,999 lakh from Rs 22,189 lakh in FY25.

Consolidated Financial Highlights

The following table summarizes the key consolidated financial metrics for the quarter and year ended March 31, 2026:

Segment Performance

The company operates primarily in two segments: Active Pharmaceutical Ingredients (API) and Real Estate. For the quarter ended March 31, 2026, the Real Estate business contributed significantly to revenue with Rs 5,021 lakh, while the API business reported revenue of Rs 983 lakh. For the full year, Real Estate revenue stood at Rs 19,340 lakh, and API revenue was Rs 4,659 lakh.

The statutory auditors, M/s. CNK & Associates LLP, issued an unmodified opinion on the consolidated and standalone financial results for the year ended March 31, 2026.